```
FILE 'HOME' ENTERED AT 00:16:49 ON 02 OCT 2006

=> b reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.63       0.63

FILE 'REGISTRY' ENTERED AT 00:18:50 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 SEP 2006  HIGHEST RN 909185-74-6
DICTIONARY FILE UPDATES:  29 SEP 2006  HIGHEST RN 909185-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> b caplus biosis sciseach medline embal embase
'SCISEACH' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):scisearch
'EMABAL' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):embal
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.44       1.07

FILE 'CAPLUS' ENTERED AT 00:19:43 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 00:19:43 ON 02 OCT 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 00:19:43 ON 02 OCT 2006
```



```
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 00:19:43 ON 02 OCT 2006

FILE 'EMBAL' ENTERED AT 00:19:43 ON 02 OCT 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 00:19:43 ON 02 OCT 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

=> s isoleucyl adj thiazolidine
L1            0 ISOLEUCYL ADJ THIAZOLIDINE

=> s isoleucyl thiazolidine
L2           15 ISOLEUCYL THIAZOLIDINE

=> s isoleucyl pyrrolidine
L3            2 ISOLEUCYL PYRROLIDINE

=> s allo isoleucyl thiazolidine
L4            0 ALLO ISOLEUCYL THIAZOLIDINE

=> s allo isoleucyl pyrrolidine
L5            0 ALLO ISOLEUCYL PYRROLIDINE

=> s valyl thiazolidine
L6            0 VALYL THIAZOLIDINE

=> s valyl pyrrolidine
L7           11 VALYL PYRROLIDINE

=> s l2 l3 l7
MISSING OPERATOR L2 L3
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l2 and l3 and l7
L8            0 L2 AND L3 AND L7

=> s l2 and dipeptidyl peptidase and inhibitor
L9           15 L2 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR

=> s l3 and dipeptidyl peptidase and inhibitor
L10           0 L3 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR

=> s l7 and dipeptidyl peptidase and inhibitor
L11           0 L7 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR

=> dup remo l9
PROCESSING COMPLETED FOR L9
L12            8 DUP REMO L9 (7 DUPLICATES REMOVED)

=> d l12 1-8 bib abs

L12  ANSWER 1 OF 8  EMBASE  COPYRIGHT (c) 2006 Elsevier B.V. All rights
     reserved on STN
AN   2005446499  EMBASE
TI   Dipeptidyl peptidase IV inhibition for the treatment
     of type 2 diabetes: Potential importance of selectivity over
```

dipeptidyl peptidases 8 and 9.
AU Lankas G.R.; Leiting B.; Roy R.S.; Eiermann G.J.; Beconi M.G.; Biftu T.; Chan C.-C.; Edmondson S.; Feeney W.P.; He H.; Ippolito D.E.; Kim D.; Lyons K.A.; Ok H.O.; Patel R.A.; Petrov A.N.; Pryor K.A.; Qian X.; Reigle L.; Woods A.; Wu J.K.; Zaller D.; Zhang X.; Zhu L.; Weber A.E.; Thornberry N.A.
CS N.A. Thornberry, Merck Research Laboratories, E. Lincoln Avenue, Rahway, NJ, United States. nancy_thornberry@merck.com
SO Diabetes, (2005) Vol. 54, No. 10, pp. 2988-2994. .
Refs: 30
ISSN: 0012-1797 CODEN: DIAEAZ
CY United States
DT Journal; Article
FS 003 Endocrinology
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
052 Toxicology
LA English
SL English
ED Entered STN: 17 Nov 2005
Last Updated on STN: 17 Nov 2005
AB Dipeptidyl peptidase (DPP)-IV inhibitors are a new approach to the treatment of type 2 diabetes. DPP-IV is a member of a family of serine peptidases that includes quiescent cell proline dipeptidase (QPP), DPP8, and DPP9; DPP-IV is a key regulator of incretin hormones, but the functions of other family members are unknown. To determine the importance of selective DPP-IV inhibition for the treatment of diabetes, we tested selective inhibitors of DPP-IV, DPP8/DPP9, or QPP in 2-week rat toxicity studies and in acute dog tolerability studies. In rats, the DPP8/9 inhibitor produced alopecia, thrombocytopenia, reticulocytopenia, enlarged spleen, multiorgan histopathological changes, and mortality. In dogs, the DPP8/9 inhibitor produced gastrointestinal toxicity. The QPP inhibitor produced reticulocytopenia in rats only, and no toxicities were noted in either species for the selective DPP-IV inhibitor. The DPP8/9 inhibitor was also shown to attenuate T-cell activation in human in vitro models; a selective DPP-IV inhibitor was inactive in these assays. Moreover, we found DPP-IV inhibitors that were previously reported to be active in models of immune function to be more potent inhibitors of DPP8/9. These results suggest that assessment of selectivity of potential clinical candidates may be important to an optimal safety profile for this new class of antihyperglycemic agents. .COPYRGT. 2005 by the American Diabetes Association.

L12 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
AN 2005:681597 CAPLUS
DN 143:186086
TI Type 2 diabetes-Therapy with dipeptidyl peptidase IV inhibitors
AU Demuth, Hans-Ulrich; McIntosh, Christopher H. S.; Pederson, Raymond A.
CS Biocenter, Probiodrug AG, Halle (Saale), D-06120, Germany
SO Biochimica et Biophysica Acta, Proteins and Proteomics (2005), 1751(1), 33-44
CODEN: BBAPBW; ISSN: 1570-9639
PB Elsevier B.V.
DT Journal; General Review
LA English

10/735,582 01 October 2006 Primary Examiner Dell Chism

AB A review. The sole application of an inhibitor of the dipeptidyl peptidase DP IV (also DP 4, CD26, DPP-IV or DPP-4) to a mammal subsequently leading to improved glucose tolerance marks a major breakthrough in metabolic research bearing the potential of a new revolutionary diabetes therapy. This was demonstrated in rat applying the specific DP IV inhibitor isoleucyl thiazolidine. It was published in 1996 for the first time that a specific DP IV inhibitor in a given dose was able to completely block glucagon-like peptide-1 (GLP-1) degradation in vivo resulting in improved insulin response accompanied, by accelerated peripheral glucose disposal. Later on, these results were confirmed by several research teams applying DP IV inhibitors i.v. or orally. Today, the DP IV inhibition for the treatment of metabolic disorders is a validated principle. Now, more than 10 years after the initial animal expts., first DP IV inhibitors as investigational drugs are tested in phase 3 clin. trials.
RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 8 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 2004386015 EMBASE
TI CD26.
AU Chen T.; Smyth D.; Abbott C.A.
CS Dr. C. Abbott, School of Biological Sciences, Flinders University, PO Box 2100, Adelaide, SA 5001, Australia. cathy.abbott@flinders.edu.au
SO Journal of Biological Regulators and Homeostatic Agents, (2004) Vol. 18, No. 1, pp. 47-54. .
Refs: 67
ISSN: 0393-974X CODEN: JBRAER
CY Italy
DT Journal; Article
FS 006 Internal Medicine
026 Immunology, Serology and Transplantation
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
ED Entered STN: 24 Sep 2004
Last Updated on STN: 24 Sep 2004
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L12 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:187761 CAPLUS
DN 139:206999
TI Inhibitor focusing: Direct selection of drug targets from proteomes using activity-based probes
AU Nomanbhoy, Tyzoon K.; Rosenblum, Jonathan; Aban, Arwin; Burbaum, Jonathan J.
CS ActivX Biosciences, Inc., La Jolla, CA, 92037, USA
SO Assay and Drug Development Technologies (2003), 1(1-2), 137-146
CODEN: ADDTAR; ISSN: 1540-658X
PB Mary Ann Liebert, Inc.
DT Journal
LA English
AB In the latter stages of drug discovery and development, assays that establish drug selectivity and toxicity are important when side effects, which are often due to lack of specificity, determine drug candidate viability.

Allowance Search

There has been no comprehensive or systematic methodol. to measure these factors outside of whole-animal assays, and such phenomenol. assays generally fail to establish the addnl. targets of a given small mol., or the mol. origin of toxicity. Consequently, small-mol. development programs destined for failure often reach advanced stages of testing, and the money and time invested in such programs could be saved if information on selectivity were available early in the process. Here, we present a methodol. that utilizes chemical ABPs in combination with small-mol. inhibitors to selectively label small-mol. binding sites in whole proteomic samples. In principle, the ABP and small mol. will compete for similar binding sites, such that the small mol. will protect against modification by the ABP. Thus, after removal of the small mol., the binding site for the ABP will be revealed, and a second probe can then be used to label the small-mol. binding sites selectively. To demonstrate this exptl., we mapped the binding sites of the dipeptidyl peptidase 4 inhibitor, isoleucyl thiazolidine, in a number of different tissue types.

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2002:6029 BIOSIS
DN PREV200200006029
TI Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals.
AU Demuth, Hans-Ulrich [Inventor, Reprint author]; Rosche, Fred [Inventor]; Schmidt, Joem [Inventor]; Pauly, Robert P. [Inventor]; McIntosh, Christopher H. S. [Inventor]; Pederson, Ray A. [Inventor]
CS Halle, Germany
ASSIGNEE: Probiodrug, Weinbergweg, Germany
PI US 6303661 20011016
SO Official Gazette of the United States Patent and Trademark Office Patents, (Oct. 16, 2001) Vol. 1251, No. 3. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 28 Dec 2001
Last Updated on STN: 25 Feb 2002
AB Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.

L12 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
AN 2000:853951 CAPLUS
DN 134:95720
TI Metabolism of glucagon by dipeptidyl peptidase IV (CD26)
AU Pospisilik, J. A.; Hinke, S. A.; Pederson, R. A.; Hoffmann, T.; Rosche, F.; Schlenzig, D.; Glund, K.; Heiser, U.; McIntosh, C. H. S.; Demuth, H.-U.
CS Department of Physiology, University of British Columbia, Vancouver, BC, V6T 1Z3, Can.
SO Regulatory Peptides (2001), 96(3), 133-141

CODEN: REPPDY; ISSN: 0167-0115
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
AB Glucagon is a 29-amino acid polypeptide released from pancreatic islet α-cells that acts to maintain euglycemia by stimulating hepatic glycogenolysis and gluconeogenesis. Despite its importance, there remains controversy about the mechanisms responsible for glucagon clearance in the body. In the current study, enzymic metabolism of glucagon was assessed using sensitive mass spectrometric techniques to identify the mol. products. Incubation of glucagon with purified porcine dipeptidyl peptidase IV (DP IV) yielded sequential production of glucagon3-29 and glucagon5-29. In human serum, degradation to glucagon3-29 was rapidly followed by N-terminal cyclization of glucagon, preventing further DP IV-mediated hydrolysis. Bioassay of glucagon, following incubation with purified DP IV or normal rat serum demonstrated a significant loss of hyperglycemic activity, while a similar incubation in DP IV-deficient rat serum did not show any loss of glucagon bioactivity. Degradation, monitored by mass spectrometry and bioassay, was blocked by the specific DP IV inhibitor, isoleucyl thiazolidine. These results identify DP IV as a primary enzyme involved in the degradation and inactivation of glucagon. These findings have important implications for the determination of glucagon levels in human plasma.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2001:2379 BIOSIS
DN PREV200100002379
TI Prodrugs of DP IV-inhibitors strongly improve incretin-mediated glucose tolerance.
AU Demuth, Hans-Ulrich [Reprint author]; Hoffmann, Torsten; Freyse, Ernst-Joachim; Berg, Sabine; Heinke, Peter; McIntosh, Christopher H. S.; Pederson, Raymond A.
CS Probiodrug Research GmbH, Halle/Saale, Germany
SO Diabetes Research and Clinical Practice, (September, 2000) Vol. 50, No. Suppl. 1, pp. S386. print.
Meeting Info.: 17th International Diabetes Federation Congress on Diabetes Research and Clinical Practice. Mexico-City, Mexico. November 05-10, 2000. International Diabetes Federation.
CODEN: DRCPE9. ISSN: 0168-8227.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 21 Dec 2000
Last Updated on STN: 21 Dec 2000

L12 ANSWER 8 OF 8 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
AN 2000416531 EMBASE
TI Metabolism of glucagon by dipeptidyl peptidase IV (CD26).
AU Pospisilik J.A.; Hinke S.A.; Pederson R.A.; Hoffmann T.; Rosche F.; Schlenzig D.; Glund K.; Heiser U.; McIntosh C.H.S.; Demuth H.U.
CS H.U. Demuth, Probiodrug Research, Biocenter, Weinbergweg 22, D-06120 Halle, Germany. hans-ulrich.demuth@probiodrug.de
SO Regulatory Peptides, (12 Jan 2001) Vol. 96, No. 3, pp. 133-141. .
Refs: 49
ISSN: 0167-0115 CODEN: REPPDY

PUI S 0167-0115(00)00170-1
CY Netherlands
DT Journal; Article
FS 003 Endocrinology
030 Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 14 Dec 2000
Last Updated on STN: 14 Dec 2000
AB Glucagon is a 29-amino acid polypeptide released from pancreatic islet α-cells that acts to maintain euglycemia by stimulating hepatic glycogenolysis and gluconeogenesis. Despite its importance, there remains controversy about the mechanisms responsible for glucagon clearance in the body. In the current study, enzymatic metabolism of glucagon was assessed using sensitive mass spectrometric techniques to identify the molecular products. Incubation of glucagon with purified porcine dipeptidyl peptidase IV (DP IV) yielded sequential production of glucagon3-29 and glucagon5-29. In human serum, degradation to glucagon3-29 was rapidly followed by N-terminal cyclization of glucagon, preventing further DP IV-mediated hydrolysis. Bioassay of glucagon, following incubation with purified DP IV or normal rat serum demonstrated a significant loss of hyperglycemic activity, while a similar incubation in DP IV-deficient rat serum did not show any loss of glucagon bioactivity. Degradation, monitored by mass spectrometry and bioassay, was blocked by the specific DP IV inhibitor, isoleucyl thiazolidine.
These results identify DP IV as a primary enzyme involved in the degradation and inactivation of glucagon. These findings have important implications for the determination of glucagon levels in human plasma.

=> d his

(FILE 'HOME' ENTERED AT 00:16:49 ON 02 OCT 2006)

FILE 'REGISTRY' ENTERED AT 00:18:50 ON 02 OCT 2006

FILE 'CAPLUS, BIOSIS, SCISEARCH, MEDLINE, EMBAL, EMBASE' ENTERED AT 00:19:43 ON 02 OCT 2006
L1 0 S ISOLEUCYL ADJ THIAZOLIDINE
L2 15 S ISOLEUCYL THIAZOLIDINE
L3 2 S ISOLEUCYL PYRROLIDINE
L4 0 S ALLO ISOLEUCYL THIAZOLIDINE
L5 0 S ALLO ISOLEUCYL PYRROLIDINE
L6 0 S VALYL THIAZOLIDINE
L7 11 S VALYL PYRROLIDINE
L8 0 S L2 AND L3 AND L7
L9 15 S L2 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR
L10 0 S L3 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR
L11 0 S L7 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR
L12 8 DUP REMO L9 (7 DUPLICATES REMOVED)

=> b pctfull uspatfull uspat2

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	82.00	83.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

Allowance Search

10/735,582 01 October 2006 Primary Examiner Dell Chism

	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

FILE 'PCTFULL' ENTERED AT 00:25:18 ON 02 OCT 2006

FILE 'USPATFULL' ENTERED AT 00:25:18 ON 02 OCT 2006

FILE 'USPAT2' ENTERED AT 00:25:18 ON 02 OCT 2006

=> s l2
L13 80 L2

=> s l3
L14 79 L3

=> s l7
L15 44 L7

=> s l13 and DIPEPTIDYL PEPTIDASE AND INHIBITOR
L16 74 L13 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR

=> s l14 and DIPEPTIDYL PEPTIDASE AND INHIBITOR
L17 71 L14 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR

=> s l15 and DIPEPTIDYL PEPTIDASE AND INHIBITOR
L18 17 L15 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR

=> dup remo l16
PROCESSING COMPLETED FOR L16
L19 69 DUP REMO L16 (5 DUPLICATES REMOVED)

=> dup remo l17
PROCESSING COMPLETED FOR L17
L20 65 DUP REMO L17 (6 DUPLICATES REMOVED)

=> dup remo l18
PROCESSING COMPLETED FOR L18
L21 16 DUP REMO L18 (1 DUPLICATE REMOVED)

=> s l19 and l20 and l21
L22 6 L19 AND L20 AND L21

=> d l22 1-6 bib abs

L22 ANSWER 1 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
AN 2004076433 PCTFULL ED 20040916 EW 200437
TIEN DIPEPTIDYL PEPTIDASE INHIBITORS
TIFR INHIBITEURS DE DIPEPTIDYLE PEPTIDASE
IN SCHARPE, Simon, Kerkhofstraat 7, B-9280 Wieze, BE [BE, BE];
AUGUSTYNS, Koen, Heike 2, B-2322 Hoogstraten, BE [BE, BE];
HAEMERS, Achiel, De Knok 2, B-9830 Sint-Martens-Latem, BE [BE, BE];
LAMBEIR, Anne-Marie, Sparrendreef 35, B-3001 Heverlee, BE [BE, BE];
DE MEESTER, Ingrid, Fort 7-straat 7, B-2610 Wilrijk, BE [BE, BE];
SENTEN, Kristel, Ringlaan 86, B-2610 Wilrijk, BE [BE, BE];
VAN DER VEKEN, Pieter, Broevink 61, B-1745 Opwijk, BE [BE, BE]
PA AIC, Drie Eikenstraat 661, B-2650 Edegem, BE [BE, BE], for all

Allowance Search

designates States except US;
SCHARPE, Simon, Kerkhofstraat 7, B-9280 Wieze, BE [BE, BE], for US only;
AUGUSTYNS, Koen, Heike 2, B-2322 Hoogstraten, BE [BE, BE], for US only;
HAEMERS, Achiel, De Knok 2, B-9830 Sint-Martens-Latem, BE [BE, BE], for US only;
LAMBEIR, Anne-Marie, Sparrendreef 35, B-3001 Heverlee, BE [BE, BE], for US only;
DE MEESTER, Ingrid, Fort 7-straat 7, B-2610 Wilrijk, BE [BE, BE], for US only;
SENTEN, Kristel, Ringlaan 86, B-2610 Wilrijk, BE [BE, BE], for US only;
VAN DER VEKEN, Pieter, Broevink 61, B-1745 Opwijk, BE [BE, BE], for US only

AG BRANTS, Johan, Philippe, Emi, De Clercq, Brants & Partners cv, E. Gevaertdreef 10a, B-9830 Sint-Martens-Latem, BE

LAF English

LA English

DT Patent

PI WO 2004076433 A1 20040910

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2003-IB792 A 20030228

ABEN The present invention relates to novel inhibitors of serine type peptidases in general and of serine type dipeptidyl peptidases in particular. The present invention further relates to the use of the dipeptidyl peptidase inhibitors for selective inhibition of dipeptidyl peptidases. The present invention also relates to pharmaceutical compositions comprising these novel dipeptidyl peptidase inhibitors. The present invention further relates to the use of the novel inhibitors in therapy, diagnosis and research.

ABFR L'invention concerne de nouveaux inhibiteurs de peptidases de type serine en general et de dipeptidyle peptidases de type serine en particulier. L'invention concerne egalement l'utilisation des inhibiteurs de dipeptidyle peptidases dans l'inhibition selective de dipeptidyle peptidases. L'invention concerne en outre des compositions pharmaceutiques comportant ces nouveaux inhibiteurs de dipeptidyle peptidases. Par ailleurs, la presente invention se rapporte a l'utilisation de ces nouveaux inhibiteurs dans les domaines therapeutique, diagnostique et de recherche.

L22 ANSWER 2 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN

AN 2003002595 PCTFULL ED 20030117 EW 200302

TIEN NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS

TIFR NOUVEAUX INHIBITEURS DE DIPEPTIDYLPEPTIDASE IV ET LEURS UTILISATIONS EN TANT QU'AGENTS ANTI-CANCEREUX

IN DEMUTH, Hans-Ulrich, Hegelstrasse 14, 06114 Halle/Saale, DE [DE, DE]; HOFFMANN, Torsten, Koernerstrasse 8, 06114 Halle/Saale, DE [DE, DE]; VON HOeRSTEN, Stephan, Birkenkamp 1, 30900 Wedemark, DE [DE, DE]

PA PROBIODRUG AG, Weinbergweg 22, 06120 Halle/Saale, DE [DE, DE], for all designates States except US;
DEMUTH, Hans-Ulrich, Hegelstrasse 14, 06114 Halle/Saale, DE [DE, DE], for US only;
HOFFMANN, Torsten, Koernerstrasse 8, 06114 Halle/Saale, DE [DE, DE], for US only;
VON HOeRSTEN, Stephan, Birkenkamp 1, 30900 Wedemark, DE [DE, DE], for US only

AG FORSTMEYER, Dietmar, Boeters & Bauer, Bereiteranger 15, 81541 Muenchen, DE

LAF English

LA English

DT Patent

PI WO 2003002595 A2 20030109

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2002-EP7129 A 20020627

PRAI EP 2001-01114796.4 20010627

DE 2001-101 50 203.6 20011012

DE 2001-101 54 689.0 20011109

US 2002-60/360,909 20020228

ABEN The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.

ABFR La presente invention concerne de nouvelles utilisations d'inhibiteurs de dipeptidylpeptidase IV (DPIV) de la presente invention, et leurs sels d'addition acides pharmaceutiquement acceptables correspondants, pour le traitement de cas induits par la DPIV ou par des enzymes du type DPIV, tels qu'un cancer et des tumeurs. Dans un mode de realisation prefere, les composes selon la presente invention sont utiles pour le traitement de la colonisation de metastases et de tumeurs.

L22 ANSWER 3 OF 6 USPATFULL on STN

AN 2006:46504 USPATFULL

TI Sustained release preparation

IN Akiyama, Yohko, C/O TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, JUSOHONMACHI 2-CHOME, YODOGAWA-KU OSAKA-SHI, OSAKA, JAPAN 532-8686
Matsumoto, Yukihiro, Osaka, JAPAN
Oi, Satoru, Osaka, JAPAN
Suzuki, Nobuhiro, Osaka, JAPAN
Tsubotani, Shigetoshi, Osaka, JAPAN

PA TAKEDA PHARMACEUTICAL COMPANY LIMITED, OSAKA, JAPAN, 541-0045 (non-U.S. corporation)

PI US 2006039974 A1 20060223

AI US 2003-526792 A1 20030910 (10)
WO 2003-JP11570 20030910
20050308 PCT 371 date
PRAI JP 2002-266054 20020911
DT Utility
FS APPLICATION
LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1580
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The sustained-release preparation of the present invention, which contains a dipeptidyl peptidase IV inhibitor and a hydrophilic polymer, can appropriately inhibit the DPP-IV activity, and is superior in convenience or compliance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 4 OF 6 USPATFULL on STN
AN 2005:234091 USPATFULL
TI Novel effectors of dipeptidyl peptidase IV
IN Demuth, Hans-Ulrich, Halle, GERMANY, FEDERAL REPUBLIC OF
Glund, Konrad, Halle, GERMANY, FEDERAL REPUBLIC OF
Schlenzig, Dagmar, Halle, GERMANY, FEDERAL REPUBLIC OF
Kruber, Susanne, Halle, GERMANY, FEDERAL REPUBLIC OF
PI US 2005203030 A1 20050915
AI US 2003-727209 A1 20031202 (10)
RLI Continuation of Ser. No. US 2003-361956, filed on 10 Feb 2003, ABANDONED
Continuation of Ser. No. US 2000-723638, filed on 28 Nov 2000, GRANTED, Pat. No. US 6548481
PRAI DE 1998-198 19980528
WO 1999-EP3712 19990528
DT Utility
FS APPLICATION
LREP BROWN, RUDNICK, BERLACK & ISRAELS, LLP., BOX IP, 18TH FLOOR, ONE FINANCIAL CENTER, BOSTON, MA, 02111, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1-18
DRWN 2 Drawing Page(s)
LN.CNT 677
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof used in the treatment of impaired glucose tolerance, glycosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and also of sequelae of diabetes mellitus in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 5 OF 6 USPATFULL on STN
AN 2005:196882 USPATFULL
TI Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
IN von Hoersten, Stephan, Wedemark, GERMANY, FEDERAL REPUBLIC OF
Demuth, Hans-Ulrich, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Hoffmann, Torsten, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF

10/735,582 01 October 2006 Primary Examiner Dell Chism

PI US 2005171025 A1 20050804
US 7109347 B2 20060919
AI US 2005-93991 A1 20050330 (11)
RLI Continuation of Ser. No. US 2002-172809, filed on 13 Jun 2002, PENDING
PRAI EP 2001-114796 20010627
DE 2001-150203 20011012
DE 2001-154689 20011109
US 2001-301158P 20010627 (60)
US 2002-360909P 20020228 (60)
DT Utility
FS APPLICATION
LREP BROWN, RUDNICK, BERLACK & ISRAELS, LLP., BOX IP, 18TH FLOOR, ONE FINANCIAL CENTER, BOSTON, MA, 02111, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2625
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 6 OF 6 USPATFULL on STN
AN 2003:188406 USPATFULL
TI Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
IN von Hoersten, Stephan, Wedemark, GERMANY, FEDERAL REPUBLIC OF
Demuth, Hans-Ulrich, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
Hoffmann, Torsten, Halle/Saale, GERMANY, FEDERAL REPUBLIC OF
PI US 2003130199 A1 20030710
AI US 2002-172809 A1 20020613 (10)
PRAI EP 2001-114796 20010627
DE 2001-150203 20011012
DE 2001-154689 20011109
US 2001-301158P 20010627 (60)
US 2002-360909P 20020228 (60)
DT Utility
FS APPLICATION
LREP Mark A. Hofer, Brown Rudnick Berlack Israels, LLP, One Financial Center, Boston, MA, 02111
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Allowance Search

10/735,582 01 October 2006 Primary Examiner Dell Chism

=> d his

(FILE 'HOME' ENTERED AT 00:16:49 ON 02 OCT 2006)

FILE 'REGISTRY' ENTERED AT 00:18:50 ON 02 OCT 2006

FILE 'CAPLUS, BIOSIS, SCISEARCH, MEDLINE, EMBAL, EMBASE' ENTERED AT 00:19:43 ON 02 OCT 2006

L1 0 S ISOLEUCYL ADJ THIAZOLIDINE
L2 15 S ISOLEUCYL THIAZOLIDINE
L3 2 S ISOLEUCYL PYRROLIDINE
L4 0 S ALLO ISOLEUCYL THIAZOLIDINE
L5 0 S ALLO ISOLEUCYL PYRROLIDINE
L6 0 S VALYL THIAZOLIDINE
L7 11 S VALYL PYRROLIDINE
L8 0 S L2 AND L3 AND L7
L9 15 S L2 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR
L10 0 S L3 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR
L11 0 S L7 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR
L12 8 DUP REMO L9 (7 DUPLICATES REMOVED)

FILE 'PCTFULL, USPATFULL, USPAT2' ENTERED AT 00:25:18 ON 02 OCT 2006
L13 80 S L2
L14 79 S L3
L15 44 S L7
L16 74 S L13 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR
L17 71 S L14 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR
L18 17 S L15 AND DIPEPTIDYL PEPTIDASE AND INHIBITOR
L19 69 DUP REMO L16 (5 DUPLICATES REMOVED)
L20 65 DUP REMO L17 (6 DUPLICATES REMOVED)
L21 16 DUP REMO L18 (1 DUPLICATE REMOVED)
L22 6 S L19 AND L20 AND L21

Allowance Search